Medicine/7. Clinical medicine
Parakhonsky
A.P.
Kuban medical
institute, Medical center "Health", Krasnodar, Russia
Functions
in immune regulation in atherosclerosis
Cardiovascular
disease is the biggest killer globally and the principal contributing factor to
the pathology is atherosclerosis; a chronic, inflammatory disorder characterized
by lipid and cholesterol accumulation and the development of fibrotic plaques
within the walls of large and medium arteries. Macrophages are fundamental to
the immune response directed to the site of inflammation and their normal,
protective function is harnessed, detrimentally, in atherosclerosis. Macrophages
contribute to plaque development by internalizing native and modified
lipoproteins to convert them into cholesterol-rich foam cells. Foam cells not
only help to bridge the innate and adaptive immune response to atherosclerosis
but also accumulate to create fatty streaks, which help shape the architecture
of advanced plaques. Foam cell formation involves the disruption of normal
macrophage cholesterol metabolism, which is governed by a homeostatic mechanism
that controls the uptake, intracellular metabolism, and efflux of cholesterol.
It has
emerged over the last 20 years that an array of cytokines, including interferon-γ,
transforming growth factor-β1, interleukin-1β, and interleukin-10, are
able to manipulate these processes. Foam cell targeting, anti-inflammatory
therapies, such as agonists of nuclear receptors and statins, are known to
regulate the actions of pro- and anti-atherogenic cytokines indirectly of their
primary pharmacological function. A clear understanding of macrophage foam cell
biology will hopefully enable novel foam cell targeting therapies to be
developed for use in the clinical intervention of atherosclerosis. Atherosclerosis
is an inflammatory disease of the wall of large- and medium-sized arteries that
is precipitated by elevated levels of low-density lipoprotein (LDL) cholesterol
in the blood. The ubiquitous monocyte, the precursor of macrophages in all
tissues, is present in every phase of atherogenesis. Monocyte-derived
macrophages are scavenging and antigen-presenting cells and they secrete
cytokines, chemokines, growth-regulating molecules, and metalloproteinases and
other hydrolytic enzymes.
Vascular
inflammation is associated with and in large part driven by changes in the
leukocyte compartment of the vessel wall. Although dendritic cells (DCs) and lymphocytes
are found in the adventitia of normal arteries, their number is greatly expanded
and their distribution changed in human atherosclerotic arteries. Macrophages,
DCs, foam cells, lymphocytes, and other inflammatory cells are found in the
intimal atherosclerotic lesions. Beneath these lesions, adventitial leukocytes
organize in clusters that resemble tertiary lymphoid tissues. Under
proatherogenic conditions, nitric oxide production from endothelial cells is
reduced and the burden of reactive oxygen species and advanced glycation end
products (AGE) is increased. Incapacitating ROS-generating NADPH oxidase or the
receptor for AGE (RAGE) has beneficial effects. Targeting inflammatory adhesion
molecules also reduces atherosclerosis. Conversely, removing or blocking IL-10
or TGF-β accelerates atherosclerosis. Regulatory T-cells and B1-cells
secreting natural antibodies are atheroprotective.
Chronic
inflammation drives the development of
atherosclerosis. Dendritic cells (DCs) are known as central mediators of
adaptive immune responses and the development of immunological memory and
tolerance. DCs are present in non-diseased arteries, and accumulate within
atherosclerotic lesions where they can be localised in close vicinity to
T-cells. Recent work has revealed important functions of DCs in regulating
immune mechanisms in atherogenesis, and vaccination strategies using DCs have
been explored for treatment of disease. However, in line with a phenotypical
and functional overlap with plaque macrophages vascular DCs were also
identified to engulf lipids, thus contributing to lipid burden in the vessel
wall and initiation of lesion growth. Furthermore, a function of DCs in
regulating cholesterol homeostasis has been revealed. Finally, phenotypically
distinct plasmacytoid dendritic cells (pDCs) have been identified within
atherosclerotic lesions.
The
phenotype of macrophages in atherosclerotic lesions can vary dramatically, from
a large lipid laden foam cell to a small inflammatory cell. Classically, the concept
of macrophage heterogeneity discriminates between two extremes called either
pro-inflammatory M1 macrophages or anti-inflammatory M2 macrophages. Polarisation
of plaque macrophages is predominantly determined by the local
micro-environment present in the atherosclerotic lesion and is rather more
complex than typically described by the M1/M2 paradigm. We will focus on two
main levels of phenotype regulation, one determined by differentiation factors
produced in the lesion and the other determined by T-cell-derived polarizati
cytokines. With foam cell formation being a key characteristic of macrophages
during atherosclerosis initiation and progression, these polarization factors
will also be linked to lipid handling of macrophages.
Pro-inflammatory
cytokines can affect intracellular lipid metabolism. A variety of effects have
been described for different cell types; hepatocyte lipid turnover pathways are
inhibited during inflammation, whereas interleukin-1β (IL-1β) reduces
intracellular cholesterol levels in fibroblasts. Levels of the pro-inflammatory
cytokines IL-1β and tumour necrosis factor-α (TNF-α) are up-regulated
at sites of formation of atherosclerotic plaques. Plaque formation is though to
begin with infiltration of monocytes to the intimal layer of the vascular wall,
followed by differentiation to macrophages and macrophage uptake of modified
lipoproteins, resulting in accumulation of intracellular lipids. The
lipid-filled cells are referred to as macrophage foam cells, a key feature of
atherosclerotic plaques. Macrophage foam cell formation is a prominent feature
of human atherosclerotic plaques, usually considered to be correlated to uptake
of and inflammatory response to oxidized low density lipoproteins (OxLDL).
However, there are alternative pathways for formation of macrophage foam cells
and the effect of such lipid loading on macrophage function remains to be fully
characterized.
Investigated
the effects of IL-1beta and TNF-alpha on macrophage foam cells in order to
assess whether presence of the pro-inflammatory cytokines improves or aggravates
macrophage foam cell formation by affecting lipid accumulation and lipid
turn-over in the cells. Investigated basal and inducible cytokine expression in
primary human macrophages either loaded with triglycerides through incubation
with very low density lipoproteins (VLDL) or with cholesterol through incubation
with aggregated low density lipoproteins (AgLDL). Analyzed how foam cell lipid
content affected secretion of three pro-inflammatory cytokines: IL-1β,
IL-6 and TNF-α, and of one chemokine: IL-8, all of which are considered
pro-inflammatory, pro-atherosclerotic, and are expressed by cells in
atherosclerotic tissue.
Differentiated
primary human macrophages or THP-1 cells were lipid loaded by uptake of aggregated
low density lipoproteins (AgLDL) or very low density lipoproteins (VLDL), and
then incubated with IL-1β (0 - 5000 pg/ml) in lipoprotein-free media for
24 h. Cells incubated in absence of cytokine utilized accumulated neutral
lipids, in particular triglycerides. Addition of exogenous IL-1beta resulted in
a dose-dependent retention of intracellular cholesterol and triglycerides.
Exchanging IL-1β with TNF-α gave a similar response. Analysis of
fatty acid efflux and intracellular fatty acid activation revealed a pattern of
decreased lipid utilization in cytokine-stimulated cells.
Formation
of triglyceride-loaded foam cells resulted in a four-fold increase in basal
IL-1β secretion, whereas cholesterol loading lacked significant effect on
IL-1beta secretion. In contrast, secretion of TNF-α and IL-6 decreased
significantly following both cholesterol and triglyceride loading, with a
similar trend for secretion of IL-8. Lipid loading did not affect cell
viability or expression of caspase-3, and did not significantly affect
macrophage ability to respond to stimulation with exogenous TNF-α. IL-1β
and TNF-α enhance macrophage foam cell formation, in part by inhibition of
macrophage intracellular lipid catabolism. If present in vivo, these mechanisms
will further augment the pro-atherogenic properties of the two cytokines.
Lipid
loading of primary human macrophages resulted in altered cytokine secretion
from cells, where effects were similar regardless of neutral lipid composition
of cells. The exception was IL-1β, where triglyceride, but not
cholesterol, lipid loading resulted in a stimulation of basal secretion of the
cytokine. It is apparent that macrophage cytokine secretion is affected by
lipid loading by lipoproteins other than OxLDL. As both VLDL and AgLDL have
been found in the vessel wall, macrophage cytokine response to uptake of these
lipoproteins may have a direct effect on atherosclerotic development in vivo.
However, macrophage neutral lipid amount and composition did not affect
cellular activation by exogenous TNF-α, making it likely that lipoprotein
lipid loading can affect foam cell cytokine secretion during basal conditions
but that the effects can be overruled by TNF-α during acute inflammation.